Genomic instability: The cause and effect of BCR/ABL tyrosine kinase

Current Hematologic Malignancy Reports

Volumn 2, Issue 2, 2007, Pages 69-74

  Skorski, Tomasz ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; CHECKPOINT KINASE 1; DOUBLE STRANDED DNA; IMATINIB; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CARCINOGENESIS; CELL ADHESION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GENE MUTATION; GENETIC DISORDER; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; REVIEW;

APOPTOSIS; CELL DIFFERENTIATION; DISEASE PROGRESSION; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, GENETIC; MUTATION; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REACTIVE OXYGEN SPECIES;

EID: 34248395579     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0010-6     Document Type: Review

References (50)

1. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557
2. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001, 411:355-365.
3. Kolibaba KS, Druker BJ: Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997, 1333:F217-F248.
4. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003, 138:819-830.
5. Bartkova J, Horejsi Z, Koed K, et al.: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
6. • Gorgoulis VG, Vassiliou LV, Karakaidos P, et al.: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913. Cells display extensive DNA damage associated with activation of cell cycle checkpoints before the malignancy occurs. The transformation process is associated with disassembly of the checkpoint machinery and DNA errors.
7. Aplan PD: Causes of oncogenic chromosomal translocation. Trends Genet 2006, 22:46-55.
8. Richardson C, Jasin M: Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000, 405:697-700.
9. Beckman KB, Ames BN: Oxidative decay of DNA. J Biol Chem 1997, 272:19633-19636.
10. Karanjawala ZE, Murphy, N, Hinton, DR, et al.: Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. Curr Cell Biol 2002, 12:397-402.
11. Vafa O, Wade M, Kern S, et al.: c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002, 9:1031-1044.
12. Yu TW, Anderson D: Reactive oxygen species-induced DNA damage and its modification: a chemical investigation. Mutat Res 1997, 379:201-210.
13. Slupphaug G, Kavli B, Krokan HE: The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res 2003, 531:231-251.
14. Limoli CL, Giedzinski E, Morgan WF, et al.: Persistent oxidative stress in chromosomally unstable cells. Cancer Res 2003, 63:3107-3111.
15. Abeysinghe SS, Chuzhanova N, Krawczak M, et al.: Translocation and gross deletion breakpoints in human inherited disease and cancer I: nucleotide composition and recombination-associated motifs. Hum Mutat 2003, 22:229-244.
16. Akman SA, O'Connor TR, Rodriguez H: Mapping oxidative DNA damage and mechanisms of repair. Ann N Y Acad Sci 2000, 899:88-102.
17. Strick R, Zhang Y, Emmanuel N, Strissel PL: Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias. Hum Genet 2006, 119:479-495.
18. Preston DL, Kusumi S, Tomonaga M, et al.: Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994, 137:S68-S97.
19. Martinelli G, Terragna C, Amabile M, et al.: Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints. Haematologica 2000, 85:40-46.
20. Bassing CH, Alt FW: The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst) 2004, 3:781-796.
21. •• Weinstock DM, Elliott B, Jasin M: A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood 2006, 107:777-780. Nonhomologous end-joining appears to be responsible for the majority of chromosomal translocations.
22. Papadopoulos PC, Greenstein AM, Gaffney RA, et al.: Characterization of the translocation breakpoint sequences in Philadelphia-positive acute lymphoblastic leukemia. Genes Chromosomes Cancer 1990, 1:233-239.
23. •• Elliott B, Richardson C, Jasin M: Chromosomal translocation mechanisms at intronic Alu elements in mammalian cells. Mol Cell 2005, 17:885-894. When DNA double-strand breaks were induced adjacent to identical Alu elements, translocations arose from single-strand annealing. With diverged Alu elements, nonhomologous end-joining predominated as the translocation mechanism.
24. Arlinghaus R, Sun T: Signal transduction pathways in Bcr-Abl transformed cells. Cancer Treat Res 2004, 119:239-270.
25. Skorski T: BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002, 21:8591-8604.
26. Nieborowska-Skorska M, Stoklosa T, Datta M, et al.: ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006, 5:994-1000.
27. Skorski T: Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002, 2:351-360.
28. Deininger M: Resistance to imatinib: mechanisms and management. J Natl Compr Cane Netw 2005, 3:757-768.
29. •• Nowicki MO, Falinski R, Koptyra M, et al.: BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004, 104:3746-3753. We showed that BCR/ABL kinase induces reactive oxygen species, which cause DNA double-strand breaks. These lesions are repaired by homologous recombination repair and nonhomologous end-joining. In leukemia cells, point mutations are introduced into the homologous recombination repair products and large deletions are introduced into the nonhomologous end-joining products.
30. Slupianek A, Nowicki MO, Koptyra M, Skorski T: BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006, 5:243-250.
31. Keeshan K, Mills KI, Cotter TG, McKenna SL: Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001, 15:1823-1833.
32. Canitrot Y, Falinski R, Louat T, et al.: p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003, 102:2632-2637.
33. Henning W, Sturzbecher HW: Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003, 193:91-109.
34. Slupianek A, Hoser G, Majsterek I, et al.: Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002, 22:4189-4201.
35. Slupianek A, Schmutte C, Tombline G, et al.: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001, 8:795-806.
36. Deutsch E, Dugray A, Abdulkarim B, et al.: BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001, 97:2084-2090.
37. Brady N, Gaymes TJ, Cheung M, et al.: Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003, 63:1798-1805.
38. Gaymes TJ, Mufti GJ, Rassool FV: Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002, 62:2791-2797.
39. Bedi A, Barber JP, Bedi GC, et al.: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995, 86:1148-1158.
40. Goldberg Z, Levav Y, Krichevsky S, et al.: Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 2004, 3:1188-1195.
41. Dierov J, Dierova R, Carroll M: BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 2004, 5:275-285.
42. Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002, 107:76-94.
43. • Calabretta B, Perrotti D: The biology of CML blast crisis. Blood 2004, 103:4010-4022. Comprehensive review of CML progression from the chronic phase to blast crisis.
44. Thompson LH, Schild D: Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001, 477:131-153.
45. •• Richardson C, Stark JM, Ommundsen M, Jasin M: Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004, 23:546-553. Overexpression of Rad51, a key element in homologous recombination repair, causes chromosomal instability.
46. Canitrot Y, Lautier D, Laurent G, et al.: Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 1999, 18:2676-2680.
47. McGill CB, Holbeck SL, Strathern JN: The chromosome bias of misincorporations during double-strand break repair is not altered in mismatch repair-defective strains of Saccharomyces cerevisiae. Genetics 1998, 148:1525-1533.
48. Lieber MR, Ma Y, Pannicke U, Schwarz K: Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003, 4:712-720.
49. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
50. •• Koptyra M, Falinski R, Nowicki MO, et al.: BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006, 108:319-327.